On July 12, the Expert Committee of China's Top 100 Pharmaceutical Industry released the "2021 China Pharmaceutical Industry Top 100 Series List"
.
This selection focuses on the innovation driving force and professional promotion of pharmaceutical industry enterprises, and evaluates from the aspects of R&D comprehensive indicators and quantitative data of R&D investment in enterprises, which has significant authority and influence
in the industry.
Founded in 1992, Kangtai Bio has focused on the research and development, production and sales of human vaccines for 30 years, and has now developed into a leading domestic innovative biopharmaceutical enterprise with a wide range of international layout, with 10 kinds of products listed (including approved emergency use), of which 60 micrograms of hepatitis B vaccine and dual-vector 13-valent pneumonia vaccine are the world's first, quadruple vaccine is domestic exclusive, and it is also the world's first enterprise
with two different technical routes of new crown vaccines approved for emergency use.
Kangtai Bio is one of the enterprises with the richest vaccine R&D platform in China, with R&D capabilities such as viral vaccines, bacterial vaccines, genetically engineered vaccines, conjugate vaccines, and multivalent vaccines; It has more than 50 patents and more than 30 varieties under research, basically covering the world's mainstream varieties
.
Facing the future, the company will continue to uphold the corporate tenet of "creating better vaccines and benefiting human health", adhere to the core values of "people-oriented, people's health", activate the endogenous power of enterprise development with scientific research and innovation, and drive new growth of enterprises with high-quality products and marketing; Continue to implement the development strategy of "bringing in" and "going out", promote the company's vaccine products to continue to go abroad and go to the international market, and is committed to becoming a world-renowned supplier of biological vaccines
.
"2021 China Top 100 Pharmaceutical Industry Series List" selection results link:
On July 12, the Expert Committee of China's Top 100 Pharmaceutical Industry released the "2021 China Pharmaceutical Industry Top 100 Series List"
.
This selection focuses on the innovation driving force and professional promotion of pharmaceutical industry enterprises, and evaluates from the aspects of R&D comprehensive indicators and quantitative data of R&D investment in enterprises, which has significant authority and influence
in the industry.
Founded in 1992, Kangtai Bio has focused on the research and development, production and sales of human vaccines for 30 years, and has now developed into a leading domestic innovative biopharmaceutical enterprise with a wide range of international layout, with 10 kinds of products listed (including approved emergency use), of which 60 micrograms of hepatitis B vaccine and dual-vector 13-valent pneumonia vaccine are the world's first, quadruple vaccine is domestic exclusive, and it is also the world's first enterprise
with two different technical routes of new crown vaccines approved for emergency use.
Kangtai Bio is one of the enterprises with the richest vaccine R&D platform in China, with R&D capabilities such as viral vaccines, bacterial vaccines, genetically engineered vaccines, conjugate vaccines, and multivalent vaccines; It has more than 50 patents and more than 30 varieties under research, basically covering the world's mainstream varieties
.
Facing the future, the company will continue to uphold the corporate tenet of "creating better vaccines and benefiting human health", adhere to the core values of "people-oriented, people's health", activate the endogenous power of enterprise development with scientific research and innovation, and drive new growth of enterprises with high-quality products and marketing; Continue to implement the development strategy of "bringing in" and "going out", promote the company's vaccine products to continue to go abroad and go to the international market, and is committed to becoming a world-renowned supplier of biological vaccines
.
"2021 China Top 100 Pharmaceutical Industry Series List" selection results link:
On July 12, the Expert Committee of China's Top 100 Pharmaceutical Industry released the "2021 China Pharmaceutical Industry Top 100 Series List"
.
This selection focuses on the innovation driving force and professional promotion of pharmaceutical industry enterprises, and evaluates from the aspects of R&D comprehensive indicators and quantitative data of R&D investment in enterprises, which has significant authority and influence
in the industry.
Founded in 1992, Kangtai Bio has focused on the research and development, production and sales of human vaccines for 30 years, and has now developed into a leading domestic innovative biopharmaceutical enterprise with a wide range of international layout, with 10 kinds of products listed (including approved emergency use), of which 60 micrograms of hepatitis B vaccine and dual-vector 13-valent pneumonia vaccine are the world's first, quadruple vaccine is domestic exclusive, and it is also the world's first enterprise
with two different technical routes of new crown vaccines approved for emergency use.
Kangtai Bio is one of the enterprises with the richest vaccine R&D platform in China, with R&D capabilities such as viral vaccines, bacterial vaccines, genetically engineered vaccines, conjugate vaccines, and multivalent vaccines; It has more than 50 patents and more than 30 varieties under research, basically covering the world's mainstream varieties
.
Facing the future, the company will continue to uphold the corporate tenet of "creating better vaccines and benefiting human health", adhere to the core values of "people-oriented, people's health", activate the endogenous power of enterprise development with scientific research and innovation, and drive new growth of enterprises with high-quality products and marketing; Continue to implement the development strategy of "bringing in" and "going out", promote the company's vaccine products to continue to go abroad and go to the international market, and is committed to becoming a world-renowned supplier of biological vaccines
.
"2021 China Top 100 Pharmaceutical Industry Series List" selection results link:
